Close Menu

Breaking News

Mount Sinai researchers investigated four cytokine proteins and found that two of them were elevated in the serum samples of SARS-CoV-2 patients who fared the worst.

The financing round was led by Asian private investment firm AT Capital and early-stage deep-tech venture capital fund Elev8.vc.

The assay uses RT-PCR and next-generation sequencing to detect coronavirus SARS-CoV-2 nucleic acids from upper respiratory nasal specimens.

The deal consists of cash, Bionano common stock, and assumption of liabilities. Bionano has also paid off $1.1 million loaned to Lineagen under the CARES act.

Streck said its collection tube maintains native cell-free DNA populations and provides sample integrity by reducing the release of cellular genomic DNA.

Quest and its foundation will provide testing services, educational programs, partnerships, and financial support estimated to be worth more than $100 million.

In using the act, the HHS applied priority-rated orders for SARS-CoV-2 diagnostic supply contracts with Becton Dickinson and Quidel through September.

The investment bank said it believes OraSure will obtain an FDA Emergency Use Authorization for its COVID-19 antigen test that could lift its stock price.

News items for in vitro diagnostics industry for the week of August 17, 2020.

The planned Lighthouse Lab follows a partnership the company announced in June to build a national COVID-19 testing lab in Cardiff.

The action will immediately allow labs to offer SARS-CoV-2 LDTs without requiring EUA, and make it voluntary for labs to take LDTs through FDA premarket review.

JPM moved to an Overweight rating on both companies from a Not Rated designation assigned during a restriction period as Thermo Fisher's potential acquisition of Qiagen played out.

Zymo Research said that the Quick SARS-CoV-2 rRT-PCR kit includes ready-to-use reaction mixtures that reduce hands-on time and eliminate human errors during the set-up process.

The financing will be used for the development and clinical validation of oncology panels for treatment selection and patient monitoring with an initial focus on NSCLC.

AmoyDx aims to develop a companion diagnostic for Merck KGaA's non-small cell lung cancer treatment Tepmetko, which was recently approved in Japan.

The firm had been distributing BGI's SARS-CoV-2 test kit but will stop distributing it effective immediately, OpGen's CEO said.

The investment banking firm forecast Fiscal Year 2021 revenues of $235.6 million, higher than the consensus Wall Street estimate of $178.4 million.

The computational method, reported in Science Translational Medicine, enables the de novo prediction of cancer-associated T-cell receptors for cancer detection.

As the US tries to get more people tested, rapid antigen tests have moved to the forefront of that effort as they can provide results more quickly than PCR-based tests.

The study currently tests 28,000 people every two weeks and will expand to 150,000 by October, with the aim to increase to 400,000 people across the country.

Avalon said that as part of the agreement it is working with Cellex to source manufacturing facilities and develop next-generation COVID-19 testing kits.

The firm said its genetic tests for breast, prostate, and colorectal cancers and melanoma assess a patient's personal cancer risks and guide personalized prevention.

Under the agreement, Unilabs will help test airline passengers flying into UAE to determine if they are infected with the virus.

The test is designed to detect the ORF1ab and nucleocapsid genes of the virus in upper respiratory specimens such as nasal swabs or nasal aspirates.

For the three months ended July 31,the firm's revenues contracted to $1.26 billion from $1.27 billion in Q3 2019, beating Wall Street analysts' average estimate of $1.21 billion.

Pages